Serum levels of neuropeptide Y in patients with chronic schizophrenia during treatment augmentation with sarcosine (results of the double-blind randomized controlled PULSAR study).
Dominik StrzeleckiMagdalena Kotlicka-AntczakBartosz KaczmarekHanna JerczyńskaAdam WysokińskiPublished in: Human psychopharmacology (2020)
The use of sarcosine does not change NPY levels. Peripheral NPY concentrations may be related to depressive symptoms in schizophrenia.